Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (symbol: VERU) is a comprehensive biopharmaceutical company dedicated to advancing treatments in men’s and women’s health, as well as oncology. The company specializes in developing and commercializing innovative pharmaceuticals and medical devices.
Veru operates through three divisions:
- Pharmaceuticals and Devices: This division focuses on treatments for conditions such as benign prostatic hyperplasia, male infertility, prostate cancer, gout, sexual dysfunction, and side effects of hormonal therapies in men. For women's health, Veru is developing treatments targeting female sexual health and advanced breast and ovarian cancers.
- Consumer Health Products: This division includes the marketing and distribution of the FC2 Female Condom, the only FDA-approved female condom that offers dual protection against sexually transmitted infections, including HIV/AIDS and unintended pregnancies. Since its introduction, FC2 has been distributed to 144 countries.
- Public Sector: Veru collaborates with international health organizations, including ministries of health and the U.N., to improve global health outcomes. The company supplies large-scale tenders, such as a multi-year contract with the South African government for FC2.
Veru is currently in late-stage development for several pivotal pharmaceuticals:
- Enobosarm: A novel selective androgen receptor modulator (SARM) being developed to enhance fat loss while preserving muscle mass in overweight or obese patients receiving GLP-1 RA drugs. Enobosarm is also under investigation for treating metastatic breast cancer.
- Sabizabulin: A microtubule disruptor in Phase 3 clinical trials aimed at treating viral-induced acute respiratory distress syndrome (ARDS), particularly in hospitalized COVID-19 patients.
Recent achievements include the FDA's clearance for a Phase 2b clinical study of enobosarm, marking significant progress in its weight loss and muscle preservation programs. The company has also initiated the enrollment of patients for this study, with results expected by the end of 2024, and a follow-up study expected to complete by mid-2025.
Financially, Veru is committed to ensuring robust funding for its ongoing projects. Recent financial updates reveal successful financing rounds and strategic partnerships, positioning the company well for future growth and development. The company is also actively working to regain compliance with Nasdaq listing requirements following delays in its SEC filings.
Veru (NASDAQ: VERU), a late clinical stage biopharmaceutical company, announced its participation in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts. Veru is focused on developing innovative medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome. The company aims to leverage this platform to showcase its latest developments and clinical progress. This participation underscores Veru's commitment to advancing therapeutic solutions in its core areas of focus.
Veru announced data from two late-breaking presentations at the American Diabetes Association's 84th Scientific Sessions held June 21-24, 2024, in Orlando, Florida. The presentations highlighted the safety and efficacy of enobosarm, a drug aimed at muscle preservation and high-quality weight loss. A pooled safety analysis (Poster #2067-LB) involving 1,027 subjects indicated that enobosarm was well-tolerated with similar adverse event rates to placebo, though elevated ALT levels were noted in 3.7% of enobosarm subjects versus 1.4% for placebo. A meta-analysis (Poster #2066-LB) involving 367 subjects showed enobosarm reduced fat mass by 6.26% and increased lean mass by 4.04% over placebo, suggesting its potential to improve weight loss quality.
Veru Inc. (NASDAQ: VERU) has adjourned its 2024 Annual Shareholders Meeting, initially scheduled for June 18, 2024, to June 27, 2024, due to a lack of quorum. The meeting was convened without any business conducted as only 49.6% of shareholders' proxies were submitted, short of the required majority. Shareholders who previously voted do not need to take any further action; their votes will be counted in the rescheduled meeting unless revoked. The record date remains April 29, 2024. Shareholders are encouraged to vote to avoid additional costs.
Veru, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol VERU, reminds shareholders to vote ahead of its 2024 Annual Meeting of Shareholders. The meeting is set for June 18, 2024, at 9:00 AM ET. Shareholders should submit their votes before the proxy voting deadline, which is also on June 18, 2024, at 9:00 AM ET. Voting can be done online or via telephone based on instructions in the Form of Proxy or Voting Instruction Form. Detailed materials are available on the company’s website.
Veru, a clinical stage biopharmaceutical company (NASDAQ: VERU), will present at the American Diabetes Association's 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida.
The company will showcase two presentations on June 22, 2024:
1. A pooled safety analysis of Enobosarm from Phase 2 and Phase 3 placebo-controlled clinical trials.
2. A meta-analysis of body composition from three randomized clinical trials, highlighting Enobosarm’s ability to preserve muscle while reducing fat.
Both presentations are scheduled from 12:30 PM to 01:30 PM EDT at the West Concourse A4-B2.
Veru (NASDAQ: VERU), a biopharmaceutical company, announced that its CEO, Mitchell Steiner, M.D., will present at the Jefferies Global Healthcare Conference on June 5, 2024, from 11:00 am to 11:25 am ET. The presentation will focus on the Phase 2b clinical program of enobosarm. Enobosarm aims to augment fat loss and prevent muscle loss when combined with GLP-1 drugs for weight loss. A live webcast of the presentation will be available on Veru's website, with an archived version accessible post-event.
Veru (NASDAQ: VERU) has announced the appointment of Dr. Steven B. Heymsfield as the Principal Investigator for its Phase 2b clinical trial of enobosarm, aimed at preserving muscle while enhancing fat loss in patients using GLP-1 RAs for weight loss.
Dr. Heymsfield is a renowned expert in body composition and obesity, with extensive experience in clinical research and over 600 peer-reviewed publications. The trial seeks to address the issue of muscle loss in weight loss treatments. Veru anticipates enrolling the trial quickly and expects data by year-end.
Veru, a biopharmaceutical company specializing in innovative medicine for oncology and viral-induced acute respiratory distress syndrome, will see its CEO, Dr. Mitchell Steiner, present a keynote at Biomed Israel 2024. The event, taking place May 21-23 in Tel Aviv, Israel, focuses on life science and technology advancements. Dr. Steiner's presentation, scheduled for May 22, will discuss the effects of GLP-1 receptor agonists on muscle loss and weight management, particularly in older sarcopenic obese patients. The session aims to explore how preserving muscle mass can enhance the effectiveness of weight loss drugs.
Veru Inc. reported fiscal 2024 second quarter financial results and provided updates on its Enobosarm high-quality weight loss clinical program. The Phase 2b clinical study of enobosarm in combination with semaglutide is actively enrolling. The company has formed a high-quality weight loss Scientific Advisory Board with five medical experts and will present at upcoming medical conferences. Veru Inc. aims to develop innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) will present at the GLP-1 Based Therapeutics Summit in Philadelphia, discussing Enobosarm, a drug to avoid muscle loss and enhance weight loss quality. The presentation aims to address muscle loss issues in weight management and the potential benefits of combining Enobosarm with a GLP-1 RA. The event is scheduled for May 15-16, 2024.
FAQ
What does Veru Inc. specialize in?
What are the main divisions of Veru Inc.?
What is the FC2 Female Condom?
What is enobosarm?
What is sabizabulin?
What recent FDA clearance did Veru receive?
What are Veru’s recent financial highlights?
Has Veru faced any compliance issues recently?
What is Veru’s role in global health?
What are the expected timelines for Veru’s clinical trials?
